At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 69 enrolled
Drug / intervention
Lipoic Aciddietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Defining the Anti-inflammatory Role of Lipoic Acid in Multiple Sclerosis
In Brief
A Phase 1 clinical trial evaluating Lipoic Acid for Multiple Sclerosis. Completed, enrolled 69 participants across 2 sites.
Detailed Summary
The purpose of this study is to learn about how the antioxidant, lipoic acid, works in the body and how it may help in the management of relapsing remitting and secondary progressive multiple sclerosis. This study will compare how subject's and healthy volunteers bodies absorb and break down the supplement. This information may help in developing new therapies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
CountriesUnited States
CollaboratorsOregon Health and Science University
Timeline
Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 2009
Enrollment StartAug 2010
Primary CompletionDec 2013
TodayJul 2026
First PostedOct 19, 2009
Enrollment StartAug 1, 2010
Primary CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 16.7 years ago
Interventions
Lipoic Aciddietary
300 mg Lipoic acid tablets from Vital Nutrients